An Observational Study of Avastin (Bevacizumab) in Patients With Colorectal Cancer

A Non-interventional Multicenter Study of First-line Avastin® (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer

This observational study will assess the progression-free survival, overall response and safety of Avastin (bevacizumab) in combination with chemotherapy in a real life setting in patients with metastatic colorectal cancer. Data will be collected from patients for approximately 2 years.

Inclusion Criteria:

• Adult patients, age >/=18 years
• Proven metastatic colorectal carcinoma
• Patients have measurable disease
• Patients are eligible to receive first-line Avastin
• Patients have signed data release form

Exclusion Criteria:

• Contra-indication to receive Avastin according to the local labeling
• Participation in a clinical study within 30 days prior to enrolment
• Patients have any other primary cancer
• Concomitant treatment with other biologics
• History of other malignant disease in the past 5 years except basal cell carcinoma